Please assess the completion status of the following clinical trial:

Trial Title: Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Chronological age ≥ 3 and chronological or bone age less than or equal to 11 years inclusive in girls;~* Chronological age ≥ 3 and chronological or bone age less than or equal to 12 years inclusive for boys~* Prepubertal~* Height SD score of \< -2~* IGF-1 SD score of \< -2~Exclusion Criteria:~* Prior treatment with rhGH, rhIGF-1, or other growth-influencing medications~* Growth failure associated with other identifiable causes (e.g., syndromes, chromosomal abnormality)~* Chronic illness such as diabetes, cystic fibrosis, etc.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Untreated (Type: NO_INTERVENTION): Observational Group
- 40 μg/kg BID (twice daily dosing) (Type: EXPERIMENTAL): Injection of rhIGF-1 40 μg/kg BID. Per protocol amendment these subjects were reassigned to receive 120 μg/kg BID. Due to the dose change, the efficacy results for these subjects were analysed in a separate subanalysis. For all outcome measures, mean and standard deviations were not calculated for this arm.
- 80 μg/kg BID (twice daily dosing) (Type: EXPERIMENTAL): Injection of rhIGF-1 80 μg/kg BID
- 120 μg/kg BID (twice daily dosing) (Type: EXPERIMENTAL): Injection of rhIGF-1 120 μg/kg BID

Based on this trial design, predict the completion outcome and termination type (if applicable).